Baird Maintains Outperform on Soleno Therapeutics, Raises Price Target to $105

Benzinga · 05/08 12:45
Baird analyst Brian Skorney maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and raises the price target from $102 to $105.